• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索患者组织参与罕见病医疗保障的路径。

Exploring the path for patient organizations to participate in medical security for rare diseases.

作者信息

Dong Tian-Tian, Xie Dong-Yi

机构信息

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.

出版信息

Front Public Health. 2025 Apr 2;13:1484286. doi: 10.3389/fpubh.2025.1484286. eCollection 2025.

DOI:10.3389/fpubh.2025.1484286
PMID:40241973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11999925/
Abstract

The participation of patient organizations in the construction of medical security systems for rare diseases is an important proposition in the theory of welfare pluralism, which indicates that individualized services and diversified connections of patient organizations can fully meet the multiple medical insurance needs of patients with rare diseases. In actual practice, however, patient organizations continue to experience institutional and structural difficulties, such as improper supervision, insufficient capacity and insufficient coordination. The theory of welfare pluralism and the developmental experience of foreign rare disease organizations have suggested that patient organizations should clarify the bridge positioning and specialized development path in the multi-subject cooperation of organizations providing medical security for rare diseases, thereby improving the efficient implementation of medical security policies for rare diseases.

摘要

患者组织参与罕见病医疗保障体系建设是福利多元主义理论中的一个重要命题,这表明患者组织的个性化服务和多元化联系能够充分满足罕见病患者的多重医保需求。然而在实际实践中,患者组织仍面临着监管不当、能力不足和协调不够等制度性和结构性困境。福利多元主义理论以及国外罕见病组织的发展经验表明,患者组织应在为罕见病提供医疗保障的多主体合作中明确桥梁定位和专业化发展路径,从而提高罕见病医疗保障政策的有效实施。

相似文献

1
Exploring the path for patient organizations to participate in medical security for rare diseases.探索患者组织参与罕见病医疗保障的路径。
Front Public Health. 2025 Apr 2;13:1484286. doi: 10.3389/fpubh.2025.1484286. eCollection 2025.
2
The Role of Patient Organizations in Shaping Research, Health Policies, and Health Services for Rare Genetic Diseases: The Dutch Experience.患者组织在塑造罕见遗传疾病研究、卫生政策和卫生服务方面的作用:荷兰经验。
Genes (Basel). 2024 Sep 3;15(9):1162. doi: 10.3390/genes15091162.
3
Healthcare costs for patients with rare diseases: Evidence from China.罕见病患者的医疗费用:来自中国的证据。
Int J Health Plann Manage. 2024 Jan;39(1):48-61. doi: 10.1002/hpm.3713. Epub 2023 Oct 10.
4
The management of rare disease patients from a grassroot perspective: the role of patients' organizations in the global recognition of rare diseases in Cameroon.基层视角下的罕见病患者管理:以喀麦隆为例看患者组织在全球罕见病认可中的作用。
Pan Afr Med J. 2024 Feb 13;47:64. doi: 10.11604/pamj.2024.47.64.38226. eCollection 2024.
5
Health service security of patients with 8 certain rare diseases: evidence from China's national system for health service utilization of patients with healthcare insurance.患者 8 种特定罕见病的医疗服务保障:来自中国医保患者医疗服务利用国家体系的证据。
Orphanet J Rare Dis. 2019 Aug 20;14(1):204. doi: 10.1186/s13023-019-1165-7.
6
[Development and perspectives of community DOTS].[社区直接观察短程疗法的发展与前景]
Kekkaku. 2009 Apr;84(4):187-201.
7
The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.医疗大数据对中国商业健康保险行业的挑战:评估与建议。
BMC Health Serv Res. 2022 Sep 22;22(1):1189. doi: 10.1186/s12913-022-08574-2.
8
Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.迈向充满活力的超老龄社会:日本的医学与社会的未来。
Geriatr Gerontol Int. 2021 Aug;21(8):601-613. doi: 10.1111/ggi.14201. Epub 2021 Jul 1.
9
Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.通过实施精准公共卫生框架,改善罕见病的诊断和护理。
Adv Exp Med Biol. 2017;1031:55-94. doi: 10.1007/978-3-319-67144-4_4.
10
An Empirical Study on the Benefits Equity of the Medical Security Policy: the China Health and Nutrition Survey (CHNS).基于中国健康与营养调查(CHNS)的医疗保障政策受益公平性的实证研究
Int J Environ Res Public Health. 2020 Feb 13;17(4):1203. doi: 10.3390/ijerph17041203.

本文引用的文献

1
On welfare pluralism, social policy and the contribution of sociology: Revisiting Robert Pinker.论福利多元主义、社会政策与社会学的贡献:重访罗伯特·平克
Front Sociol. 2023 Apr 17;8:1076750. doi: 10.3389/fsoc.2023.1076750. eCollection 2023.
2
Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.与生物制药公司互动的原则:为罕见病领域的患者倡导组织制定指南。
Orphanet J Rare Dis. 2018 Jan 22;13(1):18. doi: 10.1186/s13023-018-0761-2.
3
Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks.
关于医疗保健专业人员、患者组织和行业在欧洲参考网络中作用的立场声明。
Orphanet J Rare Dis. 2016 Jan 25;11:7. doi: 10.1186/s13023-016-0383-5.
4
Involvement of patient organisations in research and development of orphan drugs for rare diseases in europe.欧洲患者组织参与罕见病孤儿药的研发
Mol Syndromol. 2012 Nov;3(5):237-43. doi: 10.1159/000342758. Epub 2012 Sep 13.